Daily Stock List
North America Frac Sand, Inc. (NAFS)
DSR News, Penny Stock Hub, BestDamnPennyStocks, TheNextBigTrade, Wall Street Beauties, WINNINGOTC, and eliteotc.com reported on North America Frac Sand, Inc. (NAFS), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
North America Frac Sand, Inc. is a development stage company whose shares trade on the OTC Markets Group’s OTCQB. The Company owns renewable land leases with the right to extract frac sand from considerable mineral deposits located in Saskatchewan, Canada. Frac Sand is a proppant used in the oil and gas industry as a part of the hydraulic fracturing process (a way to increase flow to the wellhead). Headquartered in Calgary, Alberta, North America Frac Sand has 30,000 acres of leases and lease options.
Frac sand must have specific characteristics, including attaining certain levels of crush resistance, sphericity, as well as roundness. Therefore, it is a relatively rare commodity. The Company’s short term intention is to prove out the balance of its substantial resource.
On September 9, 2015, North America Frac Sand announced the acquisition of North America Frac Sand (CA) Ltd. and its 30,000 acres of leases. The estimation is that these leases contain 6.4 million tonnes of recoverable reserves of frac sand, and potential reserves of at least 66 million tonnes.
North America Frac Sand’s business strategy is to achieve a significant presence in the frac sand industry through developing a long term, high quality and secure supply of frac sand for the oil & gas industry in Western Canada and the North Western United States.
The Company’s strategy is also to develop and maximize the mineral deposit under its land and optioned leases, and develop a long term relationship with well service and oil & gas companies, which centers on quality service and product. In addition, North America Frac Sand’s strategy involves providing a year round supply of frac sand to customers.
The Company has established relationships with all the major well service companies. This includes several large oil & gas companies. Furthermore, it has government and municipality support as well as 1680 acres tested under lease and an additional 28000 acres under options.
North America Frac Sand, Inc. (NAFS), closed Monday's trading session at $0.22, up 69.23%, on 15,100 volume with 4 trades. The average volume for the last 60 days is 67,319 and the stock's 52-week low/high is $0.02/$0.90.
FluoroPharma Medical, Inc. (FPMI)
INO.com Market Report and TaglichBrothers reported earlier on FluoroPharma Medical, Inc. (FPMI), and today we report on the Company, here at the QualityStocks Daily Newsletter.
FluoroPharma Medical, Inc. specializes in the development of novel diagnostic imaging products that use Positron Emission Tomography (PET) technology for the detection and assessment of disease before clinical manifestation. The Company is a biopharmaceutical enterprise engaged in the discovery and development of proprietary PET imaging products to evaluate cardiac disease at the cellular and molecular levels. Patents related to FluoroPharma Medical’s portfolio of imaging compounds have been issued in the U.S, Europe, China, Japan, Canada, Australia, Finland, Portugal, Ireland and Mexico.
FluoroPharma Medical has licensed technology from the Massachusetts General Hospital in Boston, Massachusetts. The Company is based in Montclair, New Jersey. FluoroPharma Medical’s shares trade on the OT C Markets’ OTCQB.
The Company’s initial focus is the development of unique PET imaging agents. It is advancing two products in clinical trials for assessment of acute and chronic forms of coronary artery disease. The design of these first in class agents is to target, fast, myocardial cells. Other products in development include agents for the detection of inflamed atherosclerotic plaque in peripheral arteries, agents with the potential to image Alzheimer's disease, and agents that could potentially be used for imaging specific cancers.
FluoroPharma has its BFPET PET Scan Imaging Agent. BFPET is a Flourine-18 labeled tracer. The design of it is to enter the myocardial cells in direct proportion to blood flow and cell membrane potential. These are two of the most important physiological indicators upon which suitable blood supply to the heart depends. The design of BFPET has been to differentiate among those cells of the myocardium, which may be ischemic, infarcted and those that are healthy. The Phase II trial for BFPET is currently open for patient recruitment at Massachusetts General Hospital in Boston. FluoroPharma has partnered with an expert Contract Research Organization (CRO) for managing the imaging data in the BFPET Phase II study.
CardioPET™ is one of FluoroPharma's first in class PET imaging products. CardioPET™ is a perfusion and fatty acid uptake indicator. The design of it is for use as a cardiac imaging agent. It may be a more specific alternative to presently available diagnostic tests.
FluoroPharma Management believes its pharmacokinetic characteristics could be especially valuable in patients who are unable to exercise. FluoroPharma Medical announced in December of 2014 scheduled completion of enrollment in a Phase II Clinical Trial of CardioPET™ (18F FCPHA) for Assessment of Coronary Artery Disease (CAD). The CardioPET Phase II study was closed after meeting its recruitment target. The subject image data is undergoing review by an expert research partner. It is being customized for systematic reading by qualified and experienced Nuclear Cardiology practitioners.
FluoroPharma Medical, Inc. (FPMI), closed Monday's trading session at $0.24, even for the day, on 34,597 volume with 7 trades. The average volume for the last 60 days is 78,059 and the stock's 52-week low/high is $0.141/$0.55.
Drone Aviation Holding Corp. (DRNE)
RedChip, SmallCapVoice, and PennyStocks24 reported earlier on Drone Aviation Holding Corp. (DRNE), and we highlight the Company today, here at the QualityStocks Daily Newsletter.
Drone Aviation Holding Corp. provides critical aerial and land based surveillance and communications solutions to commercial and government customers. The Company is a developer of specialized lighter-than-air aerostats and tethered drones. Drone Aviation’s innovative Tethered Drones are presently being fielded to the U.S. Department of Defense and State and Local municipalities. Drone Aviation Holding is based in Jacksonville, Florida. Drone Aviation Corp. is a wholly-owned subsidiary of the Company.
Drone Aviation Holding owns and operates Florida-based Lighter Than Air Systems Corp. (LTAS). LTAS is a developer and supplier of distinctive and specialized aerial solutions to the U.S. Government, State municipalities, and commercial entities.
The design of Drone’s BOLT and SPARK Drones are to fly for up to 24 hours and carry specialized Military grade surveillance equipment. In addition, the Company’s products include the Winch Aerostat Small Platform (WASP). This is a mobile, tactical-sized aerostat, which can carry a variety of payloads in support of military operations. Typical applications include network communications and intelligence, surveillance, and reconnaissance.
Drone systems are designed and developed in-house using proprietary technologies and processes that result in compact, rapidly deployable aerostat solutions and mast based systems. Drone systems, utilizing a unique tethering capability, operate in the National Airspace within Federal Aviation Administration (FAA) guidelines for safe operations.
Drone Aviation also offers its Blimp in a Box (BiB). The BiB series of aerial surveillance systems are recognized as the most versatile and cost-effective balloon surveillance systems available. The BiB 50 and 100 systems are first-rate systems for municipal deployments for crowd management, incident response, and also other heightened security situations. This is where aerial surveillance provides situational awareness, a force multiplier, command and control and evidential video.
Today, Drone Aviation Holding announced that the WATT-200 tethered drone was approved by the FAA for operations by a major news organization. The Company’s WATT-200 is engineered and manufactured to operate safely in urban environments and securely provide live, broadcast-quality aerial video. The inventive, high-strength armored tether connects the aerial vehicle to a ground power source for long flight durations. The tether acts as a leash for additional safety.
Drone Aviation Holding Corp. (DRNE), closed Monday's trading session at $4.39, up 8.40%, on 15,552 volume with 70 trades. The average volume for the last 60 days is 1,338 and the stock's 52-week low/high is $3.90/$24.00.
Relmada Therapeutics, Inc. (RLMD)
SmallCap Network, Penny Stock Bets, StreetAuthority Financial, Dividend Opportunities, Investors Alley, and Trade of the Week reported on Relmada Therapeutics, Inc. (RLMD), and we report on the Company as well, here at the QualityStocks Daily Newsletter.
Relmada Therapeutics, Inc. is a clinical-stage, specialty pharmaceutical company. It focuses on developing novel versions of proven drug products in combination with new chemical entities, which potentially address areas of high unmet medical need in the treatment of pain. Relmada Therapeutics has a varied portfolio of four lead products at different stages of development. Listed on the OTCQB, the Company has its corporate headquarters in New York City.
Relmada’s four lead products are d-Methadone (REL-1017), its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain; topical mepivacaine (REL-1021), its orphan drug designated topical formulation of the local anesthetic mepivacaine; oral buprenorphine (REL-1028), the Company’s oral dosage form of the opioid analgesic buprenorphine; and LevoCap ER (REL-1015), Relmada’s abuse resistant, sustained release dosage form of the opioid analgesic levorphanol.
The Company announced in June that it successfully completed a Phase 1 single ascending dose (SAD) clinical study with d-Methadone (dextromethadone, REL-1017). The study results indicate that d-Methadone was generally well tolerated. A maximum tolerated dose (MTD) was attained.
Relmada Therapeutics has received a No Objection Letter (NOL) from Health Canada to conduct a multiple ascending dose (MAD) clinical study with d-Methadone (REL-1017 dextromethadone). The subsequent Phase 2 Proof of Concept Study with d-Methadone is expected to begin in the first half of next year.
Last week, Relmada Therapeutics announced topline results of a proof-of-concept pharmacokinetic study in healthy volunteers using its BuTab (REL-1028). This is its investigational, oral formulation of buprenorphine, an opioid that is widely used to treat addiction and chronic pain. The design of BuTab is to be delivered orally and reach safe and effective blood levels of buprenorphine via the gastrointestinal route of administration because of its modified release profile. At present, there are no commercially available oral formulations of buprenorphine that result in gastrointestinal absorption.
Mr. Sergio Traversa, Relmada Therapeutics’ Chief Executive Officer, said, "We are very pleased to have demonstrated for the first time that buprenorphine can be delivered at therapeutic blood levels in an orally ingestible form. These results clearly support the premise that BuTab can be a successful, first-in-class, orally ingestible buprenorphine product that we expect would be enthusiastically accepted in the multi-billion dollar market for buprenorphine products."
Relmada Therapeutics, Inc. (RLMD), closed Monday's trading session at $3.00, up 27.66%, on 49,245 volume with 63 trades. The average volume for the last 60 days is 7,392 and the stock's 52-week low/high is $2.00/$5.70.
Cell MedX Corp. (CMXC)
The Observer, StockBlogs and SECFilings.com News reported earlier on Cell MedX Corp. (CMXC), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
OTC BB-listed Cell MedX Corp. is an early development stage company. It focuses on the discovery, development, and commercialization of therapeutic products for patients with diseases, including diabetes, through developing technologies to help manage the illness and related complications. Cell MedX manufactures and distributes medical devices, which are powered by its proprietary, patented technology of low level current primarily for supporting chemical (pharmaceutical) treatments for diabetes. Cell MedX has its headquarters in Henderson, Nevada.
The Company is at the forefront of creating devices that treat chronic and acute conditions for clinical and self-management care. Cell MedX is making safe, results-oriented technologies combining electro-chemical applications and establishing new levels of treatment, called cellular medicine. In addition, by way of its wholly-owned subsidiary, Avyonce Cosmedics, Inc., the Company involves in the reselling and marketing of technology and equipment to the global wellness industry and also providing continuing education to health care professionals.
Cell MedX’s aim is to release its first lineup of commercial products early next year. It will start with its flagship product called ‘e-Balance’, which works to improve the efficacy of the client’s existing medication regimes. The e-Balance brand includes consumer product development and professional versions for use within medical facilities. The design of them are to address accelerated wound healing, abatement of diabetic neuropathies, improvement with glucose control, insulin resistance and blood pressure.
In July 2015, Cell MedX updated the timeline of its earlier announced clinical trials concerning e-Balance. Dr. John Sanderson, its Chief Medical Officer, started the following program, which aims to accurately measure and quantify e-Balance's ability to alter key metabolic pathways targeting improved blood sugar control in patients living with diabetes.
Regarding the Phase II-A Clinical Trial, recruitment for the controlled clinical trial in Orange County, California was underway and targeting 30 type 1 and type 2 diabetes patients over 6 weeks. The clinical trial is to progress over 6-8 months, with clinical end points including reduction in HbA1C independent of other factors. Moreover, investigations continue into precise metabolic changes and pathways consistent with overall improved glycemic control. The Company is also working to precisely define optimal parameters and settings based on individual discoverable factors, and is conducting selective testing to further elucidate the cell and organ level mechanism of the core technology.
Cell MedX Corp. (CMXC), closed Monday's trading session at $0.08, up 14.12%, on 58,600 volume with 6 trades. The average volume for the last 60 days is 6,664 and the stock's 52-week low/high is $0.0113/$0.81.
International Stem Cell Corp. (ISCO)
The QualityStocks Daily Newsletter would like to spotlight International Stem Cell Corp. (ISCO). Today, International Stem Cell Corp. closed trading at $5.00, up 15.74%, on 44,461 volume with 142 trades. The stock’s average daily volume over the past 60 days is 17,251, and its 52-week low/high is $1.25/$12.30.
International Stem Cell Corp. announced today that the Therapeutics Goods Administration (TGA) of Australia cleared a regulatory submission of ISCO's wholly owned subsidiary, Cyto Therapeutics, to initiate a Phase I/IIa clinical trial, dose escalation trial of human parthenogenetic stem cells-derived neural stem cells (ISC-hpNSC) in patients with moderate to severe Parkinson's disease (PD). Currently, there is no cure for PD, which is the second most common neurodegenerative disease and affects over 7 million people worldwide.
International Stem Cell Corp. (ISCO) specializes in the therapeutic applications of human stem cells and the development and commercialization of cell-based biomedical products. The company was the first to develop and perfect a new class of human stem cells called parthenogenetic stem cells, created from unfertilized human eggs. ISCO has a strong patent portfolio offering clean intellectual property and freedom to operate. The company’s stem cells present superior immune matching capabilities and can be used in millions of people regardless of sex or racial background, with minimal expectation of immune rejection after transplantation.
The company’s human stem cells have been shown to be as pluripotent as embryonic stem cells, however their creation does not involve the destruction of a viable human embryo, which effectively sidesteps the controversy and ethical dilemmas associated with the use of human embryonic stem cells. In contrast to induced pluripotent stem cells, ISCO’s stem cells do not involve manipulation of cells’ genome thereby avoiding potential safety and regulatory obstacles in clinical applications.
The company's scientists are currently focused on using its stem cells to treat severe unmet medical needs of the central nervous system (Parkinson’s disease), the liver and the eye, where cell therapy has been clinically proven but is limited due to the unavailability of safe human cells. Once the technology has been clinically validated there are an essentially unlimited number of potential applications. Because of their immune-matching ability a relatively small number of these stem cell lines could offer the potential of producing the first true stem cell bank as a means of serving populations of different immune types across the globe.
In addition to its therapeutic focus, ISCO also provides a growing revenue stream through two wholly owned subsidiaries. Lifeline Cell Technology specializes in producing primary human cells and growth media for biological research, and Lifeline Skin Care, the company manufactures and markets advanced anti-aging skincare products utilizing the company’s expertise in stem cell biology. Disclaimer
International Stem Cell Corp. Company Blog
International Stem Cell Corp. News:
International Stem Cell Corporation Receives Authorization to Initiate Phase I/IIa Clinical Trial of ISC-hpNSC for the Treatment of Parkinson's Disease
International Stem Cell Corporation Announces Launch Plans for New Nano-Compound Products
International Stem Cell Corporation Announces Operating Results for the Three- and Nine-Months Ended September 30, 2015
Legacy Ventures International, Inc. (LGYV)
The QualityStocks Daily Newsletter would like to spotlight Legacy Ventures International, Inc. (LGYV). Today, Legacy Ventures International, Inc. closed trading at $2.01, up 2.03%, on 269,450 volume with 302 trades. The stock’s average daily volume over the past 60 days is 16,784, and its 52-week low/high is $0.01/$2.50.
Legacy Ventures International, Inc. was pleased to announce that its subsidiary RM Fresh Brands Inc., a food and beverage distributor, has entered into an agreement with Sysco in Toronto, a leader in the food services industry. Ron Patel, President of RM Fresh Brands commented, "We look forward to building a strong relationship with Sysco Toronto, to expand the distribution of Boxed Water, as well as our other portfolio of products."
Legacy Ventures International, Inc. (LGYV) is an investment company seeking out high-potential businesses with big ideas that can be scaled in order to promote hyper growth. The company fuels innovation and passion by providing the capital, oversight and connections that young businesses need to reach their full potential.
Legacy is led by a highly-qualified executive team with decades of relevant industry experience. Evan Clifford, the company's chief executive officer, has spent more than 15 years building and maintaining relationships with some of North America's most influential executives. Over the past decade, he has served as a lead advisor to a collection of companies and individuals striving for personal and professional success. Likewise, Rehan Saeed, Legacy's chief financial officer, has over a decade of experience in the banking industry during which he built and managed a real estate portfolio valued at $110 million.
The company's current brand portfolio is headlined by newly-acquired RM Fresh Brands, a servicer of food and beverage retailers and distributors around the globe. RM Fresh Brands takes a unique approach to brand partnerships by maintaining a clear focus on sustainable, category-changing consumables. This strategy has helped it build an extensive portfolio of highly-desirable brands – including Boxed Water, Aloe Gloe, Uncle Si's Iced Tea and Chef 5-Minute Meals.
Following the successful acquisition of RM Fresh Brands, Legacy is in a strong strategic position to move forward with its efforts to promote sustainable growth. The company will lean on the considerable experience of its management team as it looks to build on its recent progress while promoting maximized shareholder value. Disclaimer
Legacy Ventures International, Inc. Company Blog
Legacy Ventures International, Inc. News:
Legacy Ventures Subsidiary RM Fresh Brands Completes Agreement to Supply Products to Sysco for Distribution
Legacy Ventures Now Blue Sky Compliant
Robert Davi Joins Legacy Ventures
Nutra Pharma Corp. (NPHC)
The QualityStocks Daily Newsletter would like to spotlight Nutra Pharma Corp. (NPHC). Today, On the Move Systems, Inc. closed trading at $0.0849, off by 10.63%, on 351,358 volume with 23 trades. The stock’s average daily volume over the past 60 days is 166,606, and its 52-week low/high is $0.0025/$0.27.
Nutra Pharma Corp. today announces that it has engaged the Corporate Communications Services of QualityStocks. Based in Scottsdale, Arizona, QualityStocks has assisted more than 300 public companies with their efforts to broaden influence, attract growth capital and improve shareholder value over the past 9 years and 11 months.
Nutra Pharma Corp. (NPHC) is a biotech company working in collaboration with its subsidiaries to develop an innovative pipeline of biopharmaceutical products for the management of neurological disorders, cancer, autoimmune, and infectious diseases. At the core of Nutra Pharma's intellectual property is a unique platform for extracting neurotoxins from Asian cobra venom and transforming them into non-toxic therapeutics.
The ReceptoPharm subsidiary, Nutra Pharm's drug discovery arm, is focused on the development of new therapeutic agents based upon specialized receptor-binding proteins found in nature, especially those found in snake venom from the cobra. ReceptoPharm's R&D pipeline consists of several novel therapies in various stages of development to prevent and/or treat multiple sclerosis (MS), human immunodeficiency virus (HIV), adrenomyeloneuropathy (AMN), herpes, rheumatoid arthritis (RA) and pain. The subsidiary also provides small and start-up biotech companies a full range of contract research services through its ISO class 5 and GMP certified facilities in Plantation, Florida.
Nutra Pharma recently received Orphan Drug Status from the FDA for the treatment of pediatric MS for its drug, RPI-78M. The designation of RPI-78M as an Orphan Drug provides Nutra Pharma with a seven-year period of market exclusivity in the U.S. once the drug is approved. Additional benefits over conventional drug applications include: tax credits for clinical research costs, the ability to apply for grant funding, clinical trial design assistance, plus assistance from the FDA in the drug development process and the waiver of Prescription Drug User Fee Act (PDUFA) filing fees which could be in excess of $2.5 million. The granting of Orphan Drug Designation allows Nutra Pharma to move forward with its preparation of an Investigative New Drug Application and proposal of clinical trials. The FDA grants Orphan Drug Designation status to products that treat rare diseases, providing incentives to sponsors developing drugs or biologics.
ReceptoPharm holds all of the intellectual property for Nutra Pharma's drug pipeline, while Nutra Pharma directly holds all of the property dealing with their over-the-counter drugs. This includes Nyloxin, an OTC pain reliever for humans, and Pet Pain-Away, a pain reliever for dogs and cats. The company's Nyloxin product is the first OTC pain reliever clinically proven to treat moderate to severe chronic pain. The drug is available as an oral spray for treating lower back pain, migraines, neck aches, shoulder pain, cramps and neuralgia and as a topical gel for treating joint pain and pain associated with repetitive stress and arthritis.
Nutra Pharma is a revenue-generating company with 12 patents and patents pending, three completed phase 1/phase 2 clinical trials, and 12 FDA-registered OTC products in the United States. The company also has regulatory clearance for Nyloxin in India, where management believes its initial distribution streams could become the company's biggest market. Management is also defining its plan to expand into China and Canada while strengthening its position the United States. Disclaimer
Nutra Pharma Corp. Company Blog
Nutra Pharma Corp. News:
Nutra Pharma Corp. (NPHC) Announces Engagement of QualityStocks Corporate Communications Suite
Nutra Pharma Announces Additional Orphan Drug Application for RPI-78M for the Treatment of Myasthenia Gravis
StockNewsNow.com Publishes New SNNLive Video Interview With Nutra Pharma Corporation
Oakridge Global Energy Solutions, Inc. (OGES)
The QualityStocks Daily Newsletter would like to spotlight Oakridge Global Energy Solutions, Inc. (OGES). Today, On the Move Systems, Inc. closed trading at $0.53, up 3.92%, on 15,445 volume with 8 trades. The stock’s average daily volume over the past 60 days is 20,434, and its 52-week low/high is $0.15/$2.40.
Oakridge Global Energy Solutions, Inc. (OGES) specializes in the development of cutting-edge technology to transform and synchronize freight supply chain operations for a broad range of industries. The company is exploring new online tools to reduce costs and increase convenience in the tourism and travel industry, as well as new opportunities in trucking. OMVS works with a premier group of international providers to offer its services in two key divisions: Trucking Logistics and Inter-modal Freight.
Logistics are critical to the success of any operation. OMVS's Trucking Logistics division operates as one of the most competitive, full-service transportation logistics providers in the United States. Utilizing the company's ISTx Platform, this division helps customers strategize how to get from one point to another, as well as solves some of the toughest logistics challenges on the road today. OMVS's Trucking Logistics technology provides customers increased visibility, minimal-cost route effectiveness, and delivery assurance.
OMVS's Intermodal Freight division offers seamless cargo continuation, tracking, shipping and receiving of goods anywhere in the world. The company's customer service teams and drivers communicate through the ISTx Platform allowing for flexibility, control and monitoring of each freight shipment. OMVS continues to research and explore the most effective and resourceful tools in order to effectively serve customers with unique shipping requirements in the billion dollar trucking industry.
In his more than 20 years of experience, OMVS president and CEO Robert Wilson has cultivated vast expertise as an executive and financial consultant for companies in aviation, energy, oil and gas, IT and healthcare. In addition to his work valuing and assessing small-to-middle market companies, Wilson has also served as both an officer and director of such client companies. Wilson applies his expertise in the transportation business and investment banking to spearhead OMVS's new initiative to create a new kind of online transportation platform to an international market. Disclaimer
Oakridge Global Energy Solutions, Inc. Company Blog
Oakridge Global Energy Solutions, Inc. News:
Oakridge Global Energy Solutions to Be Highlighted on FOX Business Network’s “New To The Street”
Oakridge Global Energy Solutions Announces Q3 Results
Oakridge Global Energy Solutions to Be Showcased In Upcoming “New To The Street” Series
Hemp, Inc. (HEMP)
The QualityStocks Daily Newsletter would like to spotlight Hemp, Inc. (HEMP). Today, Hemp, Inc. closed trading at $0.054, up 0.56%, on 1,632,232 volume with 139 trades. The stock’s average daily volume over the past 60 days is 3,543,324, and its 52-week low/high is $0.039/$1.00.
Hemp, Inc. (HEMP) is engaged in the research and development of all things made of industrial hemp. From fabric, paper, cosmetics, food and jewelry to pulp, fuel, paints and more, the application of hemp represents a myriad of possibilities. The company strategizes to recognize the profits that could be made in making the world a better place through the industrial commercialization of this resource.
Hemp, Inc. subsidiaries include Industrial Hemp Manufacturing, LLC, which will soon be offering DrillWall™ for maintaining the seals on drilling for water, oil, gas and any other liquid or gas; and The Industrial Hemp and Medical Marijuana Consulting Company, Inc., which pulls pertinent market information from a vast network of professionals, specialists and experts from various niches of the hemp industry.
Las Vegas-based Hemp, Inc. conducts its operations through its 70,000-square-foot processing plant and decortication line of equipment, which is useful manufacturing more than 50,000 commercial products. The company's current line of offerings include hemp-infused body candles, shampoo and conditioner, smoothies, jewelry, healing oils, twine, lip balm and skin moisturizers.
Hemp products are used all over America every day and are sold in the largest and most respected stores. Not to be confused with marijuana, hemp does not contain psychoactive compounds and is legal in the United States and most of the world. Hemp, Inc.'s mission is to educate the public on this important differentiation while working to expand corporate infrastructure and invest in profitable, legal and diversified ventures poised to bring reward and value to shareholders. Disclaimer
Hemp, Inc. Company Blog
Hemp, Inc. News:
Hemp, Inc. CEO Receives the 1st Annual Jack Herer Cannabis Hemp Award
Two Days Left to Buy Hemp Jeans by Hemp Blue
National Hemp Association (NHA) Introduces Hemp, Inc. as Its Newest Gold Member
Today's Top 3
Wall Street Resources
The QualityStocks Public Company Sponsor News
- Get profiles for new featured companies at clients.qualitystocks.net
- Alternet Systems, Inc. (ALYI) CEO Featured in Exclusive QualityStocks Interview
- Avant Diagnostics, Inc. (AVDX) Receives FDA IRB Approval for OvaDx(R) Ovarian Cancer Validation Test Specimens
- Cherubim Interests, Inc. (CHIT) Announces End of Year Convertible Preferred Stock Dividend
- Dominovas Energy Corp. (DNRG) Signs Financing Agreement With GHS Capital
- Elephant Talk Communications Corp. (ETAK) Announces the Appointment of Robert H. Turner as Executive Chairman; Names ETNA President Tim Payne as Interim CEO
- Freedom Leaf Inc. (FRLF) Licensing Its Brand for National Growth on the Grass Roots Level
- Giggles N' Hugs, Inc. (GIGL) Signs Agreement with New York-Based Chardan Capital Markets
- GTX Corp. (GTXO) Launches New Track My Workforce Mobile App and Tracking Portal
- Hemp, Inc. (HEMP) CEO Receives the 1st Annual Jack Herer Cannabis Hemp Award
- International Stem Cell Corporation Receives Authorization to Initiate Phase I/IIa Clinical Trial of ISC-hpNSC for the Treatment of Parkinson's Disease
- Latitude 360, Inc. (LATX) Multi-Dimensional Entertainment Eatery Enhances Guest Experience and Engagement Through Partnership With MyCheck
- Legacy Ventures Subsidiary RM Fresh Brands Completes Agreement to Supply Products to Sysco for Distribution
- Lingo Media Corp. (LMDCF) Continues to Generate Strong Profits with Q3 Net Income of $631,730
- Moxian, Inc. (MOXC) MissionIR Exclusive Audio Interview With Moxian Creative & Marketing VP Edmund Ooi
- Nutra Pharma Corp. (NPHC) Announces Engagement of QualityStocks Corporate Communications Suite
- Oakridge Global Energy Solutions, Inc. (OGES) to Be Highlighted on FOX Business Network’s “New To The Street”
- OurPet's Company (OPCO) Dean Tsengas Named Chief Operations Officer of OurPet's Company
- Star Mountain Resources Inc. (SMRS) Closes Acquisition of Balmat Zinc Mine in New York State
- WRIT Media Group, Inc. (WRIT) Retro Infinity Kickstarter Campaign to Open an Awesome, Innovative Way to Play Classic Video Games